From Casetext: Smarter Legal Research

Perham v. GlaxoSmithKline LLC (In re Zofran (Ondansetron) Prods. Liab. Litig.)

United States Court of Appeals, First Circuit
Jan 12, 2023
No. 21-1517 (1st Cir. Jan. 12, 2023)

Opinion

21-1517

01-12-2023

IN RE: ZOFRAN (ONDANSETRON) PRODUCTS LIABILITY LITIGATION v. GLAXOSMITHKLINE LLC, Defendant, Appellee, HEATHER PERHAM, et al., Plaintiffs, Appellants, SUN PHARMACEUTICAL INDUSTRIES LTD.; SANDOZ, INC.; PROVIDENCE HEALTH SYSTEM; NOVARTIS PHARMACEUTICALS CORP.; MCKESSON CORPORATION; DOES 1 through 100, inclusive, TEVA PHARMACEUTICAL USA; GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC., Defendants.


ERRATA SHEET

The opinion of this Court issued on January 9, 2022, is amended as follows:

On page 3, line 24, "U.S.C.A." is replaced with "U.S.C."


Summaries of

Perham v. GlaxoSmithKline LLC (In re Zofran (Ondansetron) Prods. Liab. Litig.)

United States Court of Appeals, First Circuit
Jan 12, 2023
No. 21-1517 (1st Cir. Jan. 12, 2023)
Case details for

Perham v. GlaxoSmithKline LLC (In re Zofran (Ondansetron) Prods. Liab. Litig.)

Case Details

Full title:IN RE: ZOFRAN (ONDANSETRON) PRODUCTS LIABILITY LITIGATION v…

Court:United States Court of Appeals, First Circuit

Date published: Jan 12, 2023

Citations

No. 21-1517 (1st Cir. Jan. 12, 2023)